JP2013516469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516469A5 JP2013516469A5 JP2012548078A JP2012548078A JP2013516469A5 JP 2013516469 A5 JP2013516469 A5 JP 2013516469A5 JP 2012548078 A JP2012548078 A JP 2012548078A JP 2012548078 A JP2012548078 A JP 2012548078A JP 2013516469 A5 JP2013516469 A5 JP 2013516469A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- human
- antigen
- immune response
- stimulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 230000028993 immune response Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000004936 stimulating effect Effects 0.000 claims 4
- 108010040721 Flagellin Proteins 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 206010022000 influenza Diseases 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 101710154606 Hemagglutinin Proteins 0.000 claims 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 1
- 101710176177 Protein A56 Proteins 0.000 claims 1
- 230000005875 antibody response Effects 0.000 claims 1
- 239000000185 hemagglutinin Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000000277 virosome Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29259310P | 2010-01-06 | 2010-01-06 | |
| US61/292,593 | 2010-01-06 | ||
| PCT/US2011/020159 WO2011084967A2 (en) | 2010-01-06 | 2011-01-05 | Methods and compositions for providing protective immunity in the elderly |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013516469A JP2013516469A (ja) | 2013-05-13 |
| JP2013516469A5 true JP2013516469A5 (enExample) | 2014-02-20 |
Family
ID=44306116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548078A Pending JP2013516469A (ja) | 2010-01-06 | 2011-01-05 | 高齢者に保護免疫を提供するための方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130095130A1 (enExample) |
| EP (1) | EP2521563B1 (enExample) |
| JP (1) | JP2013516469A (enExample) |
| KR (1) | KR20120129893A (enExample) |
| CN (1) | CN102740872A (enExample) |
| AU (1) | AU2011203740B2 (enExample) |
| CA (1) | CA2786306A1 (enExample) |
| MX (1) | MX2012007916A (enExample) |
| SG (1) | SG182305A1 (enExample) |
| WO (1) | WO2011084967A2 (enExample) |
| ZA (1) | ZA201205273B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2594612A1 (en) | 2005-01-19 | 2006-07-27 | Vaxinnate Corporation | Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response |
| ES2555544T3 (es) | 2006-03-07 | 2016-01-04 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
| AU2009236585B2 (en) | 2008-04-18 | 2013-03-07 | Vaxinnate Corporation | Deletion mutants of flagellin and methods of use |
| US8932598B2 (en) * | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976552A (en) * | 1995-04-28 | 1999-11-02 | Protein Sciences Corporation | Virus vaccines |
| US20030232055A1 (en) * | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
| US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
| JP5094407B2 (ja) * | 2004-12-16 | 2012-12-12 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | Ｙｅｒｓｉｎｉａｐｅｓｔｉｓの免疫療法におけるフラジェリンの使用 |
| US20090162400A1 (en) * | 2004-12-21 | 2009-06-25 | Powell Thomas J | Compositions of influenza viral proteins and methods of use thereof |
| WO2006069262A2 (en) * | 2004-12-21 | 2006-06-29 | Vaxinnate Corporation | Compositions of influenza viral proteins and methods of use thereof |
| CA2596079A1 (en) * | 2005-01-31 | 2006-08-10 | Vaxinnate Corporation | Novel polypeptide ligands for toll-like receptor 2 (tlr2) |
| PE20061428A1 (es) * | 2005-03-23 | 2007-01-16 | Glaxosmithkline Biolog Sa | Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl |
| ES2555544T3 (es) * | 2006-03-07 | 2016-01-04 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
| AU2009236585B2 (en) * | 2008-04-18 | 2013-03-07 | Vaxinnate Corporation | Deletion mutants of flagellin and methods of use |
| JP2011519834A (ja) * | 2008-04-25 | 2011-07-14 | インスティチュート フォー システムズ バイオロジー | フラジェリンポリペプチドワクチン |
-
2011
- 2011-01-05 EP EP11732058.0A patent/EP2521563B1/en not_active Not-in-force
- 2011-01-05 KR KR1020127019714A patent/KR20120129893A/ko not_active Ceased
- 2011-01-05 AU AU2011203740A patent/AU2011203740B2/en not_active Ceased
- 2011-01-05 JP JP2012548078A patent/JP2013516469A/ja active Pending
- 2011-01-05 US US13/519,912 patent/US20130095130A1/en not_active Abandoned
- 2011-01-05 CN CN2011800069618A patent/CN102740872A/zh active Pending
- 2011-01-05 CA CA2786306A patent/CA2786306A1/en not_active Abandoned
- 2011-01-05 WO PCT/US2011/020159 patent/WO2011084967A2/en not_active Ceased
- 2011-01-05 SG SG2012048617A patent/SG182305A1/en unknown
- 2011-01-05 MX MX2012007916A patent/MX2012007916A/es not_active Application Discontinuation
-
2012
- 2012-07-16 ZA ZA2012/05273A patent/ZA201205273B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7523897B2 (ja) | 呼吸器合胞体ウイルス（ｒｓｖ）ワクチン | |
| Al-Halifa et al. | Nanoparticle-based vaccines against respiratory viruses | |
| Sulczewski et al. | Nanoparticle vaccines against viral infections | |
| Zaman et al. | Strategies for intranasal delivery of vaccines | |
| Tao et al. | M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection | |
| Crisci et al. | Virus-like particles: the new frontier of vaccines for animal viral infections | |
| Jabbal-Gill | Nasal vaccine innovation | |
| JP2011250797A5 (enExample) | ||
| JP2017538672A5 (enExample) | ||
| JP2013530158A5 (enExample) | ||
| JP2013518052A5 (enExample) | ||
| TW201427724A (zh) | 經鼻流感疫苗組成物 | |
| US10874737B2 (en) | Influenza nanovaccine | |
| RU2017137357A (ru) | Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал | |
| Jang et al. | Cross-protective immune responses elicited by live attenuated influenza vaccines | |
| Hashemzadeh et al. | Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus | |
| Cossette et al. | Intranasal subunit vaccination strategies employing nanomaterials and biomaterials | |
| JP2010506926A5 (enExample) | ||
| Zhao et al. | Adjuvant-free, self− assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses | |
| JP2012102105A5 (enExample) | ||
| Nesovic et al. | Delivery of gold nanoparticle-conjugated M2e influenza vaccine in mice using coated microneedles | |
| Wang et al. | The potential adjuvanticity of quaternized chitosan hydrogel based microparticles for porcine reproductive and respiratory syndrome virus inactivated vaccine | |
| Zhang et al. | Cationic nanoparticle-stabilized vaccine delivery system for the H9N2 vaccine to promote immune response in chickens | |
| Zhao et al. | Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine | |
| Nie et al. | Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice |